# Natera multi-cancer early detection assay

Source: https://onco.cc/drugs/natera-mced/  
OnCo record `natera-mced` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Natera's blood test in development for several cancers, given FDA Breakthrough Device designation in October 2026 on data from 12 cancer types; no performance figures have been published.

## Summary

Natera announced on 9 October 2026 that the FDA had granted Breakthrough Device designation to its multi-cancer early detection assay, which analyses cell-free DNA in blood. The company says the FDA considered sensitivity, specificity and cancer signal origin data from 12 cancer types; it did not name the cancers or give any figures, and the release states that its tests have not been cleared or approved by the FDA. No product name, peer-reviewed paper, registered trial, launch date or price was found on 3 November 2026.

## Fields

- Kind: Test
- Status: emerging
- Last checked: 2026-11-03
- Tags: test; mced; evidence:insufficient
- Brand: Natera MCED
- Modality: Multi-cancer early detection blood test in development (cell-free DNA)
- Mechanism: Analyses cell-free DNA in blood to screen for several cancers and to predict the cancer signal origin; Natera has not published how.

## Notes

- Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.
- A Breakthrough designation speeds FDA review; it is not an approval and says nothing about benefit.
- What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening).

## Sources

- Natera: Breakthrough Device designation (9 October 2026): https://investor.natera.com/news/news-details/2026/FDA-Grants-Breakthrough-Device-Designation-for-Nateras-Multi-Cancer-Early-Detection-Assay/default.aspx

## Connected records

- drugs: [Galleri](https://onco.cc/drugs/galleri/), [Shield MCD (Shield Multi-Cancer Detection)](https://onco.cc/drugs/shield-mcd/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- companies: [Natera](https://onco.cc/companies/natera/)

---
JSON: https://onco.cc/api/v1/entities/natera-mced.json